107 related articles for article (PubMed ID: 24292539)
1. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
[No Abstract] [Full Text] [Related]
2. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Tiribelli M; Bonifacio M; Calistri E; Binotto G; Maino E; Marin L; Guardalben E; Branca A; Gherlinzoni F; Semenzato G; Sancetta R; Pizzolo G; Fanin R
Leuk Res; 2013 Nov; 37(11):1457-60. PubMed ID: 23993428
[TBL] [Abstract][Full Text] [Related]
3. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Tiribelli M; Binotto G; Calistri E; Maino E; Scaffidi L; Medeot M; Nabergoj M; Ambrosetti A; Semenzato G; Fanin R; Bonifacio M;
Am J Hematol; 2015 Jul; 90(7):E135-7. PubMed ID: 25808917
[No Abstract] [Full Text] [Related]
4. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
5. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
[TBL] [Abstract][Full Text] [Related]
6. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
[No Abstract] [Full Text] [Related]
7. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Ashariati A; Ugroseno S
Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
[TBL] [Abstract][Full Text] [Related]
8. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
10. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
11. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome.
Koshiyama DB; Capra ME; Paskulin GA; Rosa RF; Oliveira CA; Vanelli T; Fogliatto LM; Zen PR
Ann Hematol; 2013 Jan; 92(2):185-9. PubMed ID: 23064942
[TBL] [Abstract][Full Text] [Related]
13. ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
Etienne G; Dulucq S; Lascaux A; Schmitt A; Bidet A; Fort MP; Lippert E; Bureau C; Adiko D; Hayette S; Reiffers J; Nicolini FE; Mahon FX
Am J Hematol; 2015 Jan; 90(1):37-41. PubMed ID: 25293449
[TBL] [Abstract][Full Text] [Related]
14. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
15. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
16. Imatinib and regression of type 2 diabetes.
Veneri D; Franchini M; Bonora E
N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
[No Abstract] [Full Text] [Related]
17. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
18. [THE STUDY OF RESPONSE TO TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA DEPENDING ON SOCAL SCORE].
T P; L D
Lik Sprava; 2015; (1-2):97-102. PubMed ID: 26118036
[TBL] [Abstract][Full Text] [Related]
19. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
